|1.||Jeong, Jae-Wook: 6 articles (12/2013 - 05/2009)|
|2.||DeMayo, Francesco J: 6 articles (07/2013 - 05/2009)|
|3.||Lydon, John P: 5 articles (07/2013 - 05/2009)|
|4.||Palareti, Gualtiero: 5 articles (01/2010 - 05/2005)|
|5.||Cosmi, Benilde: 5 articles (01/2010 - 05/2005)|
|6.||Fodor, L: 5 articles (01/2005 - 08/2000)|
|7.||Somogyvári, F: 5 articles (01/2005 - 08/2000)|
|8.||Szabó, M: 5 articles (01/2005 - 08/2000)|
|9.||Szolnoki, Z: 5 articles (01/2005 - 08/2000)|
|10.||Legnani, Cristina: 4 articles (01/2010 - 05/2005)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
11/01/2003 - "The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism."
04/08/2002 - "Clinical management studies are clarifying the role of D-ds in the diagnostic paradigm of VTE: negative ultrasound and D-d findings obviate the need for serial imaging in suspected deep vein thrombosis, and anticoagulant therapy can be safely withheld in patients with non-high clinical suspicion for pulmonary embolism and non-high probability ventilation perfusion scan if D-d test results are negative. "
04/08/2002 - "More recently, the combination of a negative SimpliRED (AGEN Biomedical Ltd, Brisbane, Australia) D-d result and low clinical suspicion derived using a formal scoring system has been shown to exclude deep vein thrombosis and pulmonary embolism and to obviate the need for imaging. "
12/01/1996 - "Patients with deep venous thrombosis showed a significant increase in F, FVII, tPA and D-D levels compared to controls, whereas a significant reduction was observed in PAI-1. "
08/01/1998 - "A qualitative (Instantia) and a quantitative (VIDAS D-Dimer) D-Dimer test have been evaluated and compared with an ELISA method (Asserachrom D-D) in a population of 74 patients suspected of presenting a deep vein thrombosis. "
09/01/2011 - "Positive results occurred earlier in modified plasma protamine paracoagulation test than in plasma protamine paracoagulation and D-D tests in 5 cases of myocardial infarction. "
05/20/2002 - "D/D prevalence was found higher in patients with family anamnesis of myocardial infarction (p < 0.05). "
06/01/1995 - "The female population showed an excess of ischemic electrocardiographic changes or definite myocardial infarctions in the patients homozygous for the deletion [D/D; odds ratio (OR) 2.8; 95% confidence interval (CI) 1.4-5.3] and in the insertion/deletion heterozygotes (I/D; OR 1.8; CI 1.1-3.1) compared with the patients homozygous for the insertion (I/I). "
03/15/1995 - "The D/D genotype, which is associated with higher levels of circulating ACE than the I/D or I/I genotype, has been found significantly more frequently in patients with myocardial infarction and also in individuals with a parental history of myocardial infarction. "
03/01/2012 - "In a Chinese elderly population, ACE polymorphism may be considered "deleterious" to longevity, the D/D genotype being associated with mortality, the atherosclerotic process, hypertension and myocardial infarction. "
11/01/2003 - "We can conclude that the ACE D/D genotype is protective against idiopathic venous thromboembolism."
11/01/2003 - " D/D genotype has not been evaluated as a risk factor for idiopathic venous thromboembolism (VTE). "
01/21/2010 - "The PROLONG randomized trial showed that a normal D-dimer (D-d) 1 month after anticoagulation suspension for unprovoked venous thromboembolism (VTE) was associated with a low risk of late recurrences (4.4% patient years). "
11/01/2009 - "The PROLONG study showed that D-dimer (D-d) testing could help tailor the duration of anticoagulation after idiopathic venous thromboembolism (VTE). "
05/01/2005 - "We assessed the predictive value of D-dimer (D-d) and residual venous obstruction (RVO), alone or in combination, for recurrent venous thromboembolism (VTE) over a 2-year follow-up in a cohort of 88 cancer patients after oral anticoagulant therapy (OAT) withdrawal following a first episode of proximal deep vein thrombosis of the lower limbs. "
|4.||Hypertension (High Blood Pressure)
06/01/1993 - "All six devices maintained their overall grading or improved them slightly in the low and medium blood pressure ranges, but in the high blood pressure range the CH-Druck slipped from an overall A/A grading to B/C, the Profilomat from B/A to C/D, the SpaceLabs from B/B to C/C and the Pressurometer IV from C/D to D/D. "
12/01/2015 - "The subjects with the D/D homozygote displayed lower amplitude and longer latency of P300, although there were no differences in CASI score and the percentage of hypertension. "
07/01/2012 - "This suggested that ACE (D/D) genotypes are more prone for the development of hypertension. "
12/01/2006 - "In conclusion, ACE D/D homozygosis, independently of several confounding factors, associates with higher TERalb in men with essential hypertension. "
05/01/2004 - "A significant interaction have been shown up between D/D genotype and arterial hypertension (HTA) (2 de Wald = 16.10; p > 0.001). "
09/01/2011 - "The modified plasma protamine paracoagulation test has a higher sensitivity than plasma protamine paracoagulation test and a higher specificity than D-D test, and can be helpful in early diagnosis of thrombosis and fibrinolysis."
11/01/2003 - "The deletion/deletion (D/D) genotype of the angiotensin converting enzyme (ACE) has been purported to be a risk for post-operative thrombosis.This"
01/01/2010 - "In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can be of help to establish the optimal duration of VKA treatment; among them, the D-dimer (D-d) assay and the Residual Vein Thrombosis (RVT) assessment by Compression Ultra-Sonography (CUS) were shown to be the most suitable. "
12/01/1996 - "In the light of these results the authors affirm that: high fibrinogen and factor VII levels are highly prognostic for thrombosis in patients with deep venous thrombosis; the importance of the lack of inhibitory factors (AT III, PC, PS) is confined to individual genetically predisposed cases; there is an efficacious hyperfibrinolytic reactive response to the presence of thrombus (increase in tPA and D-D, reduction of PAI-1)."
12/01/1994 - "In patients with AAA, the levels of fibrin/fibrinogen degradation products (FDP) (11.4 +/- 20.1 micrograms/ml), thrombin-antithrombin III complex (TAT) (22.0 +/- 21.8 micrograms/l), plasmin-alpha 2 plasmin inhibitor complex (PIC) (2.6 +/- 2.9 micrograms/ml) and d-dimer of cross-linked fibrin degradation products (D-D) (8.4 +/- 10.8 micrograms/ml) were elevated, particularly when the AAAs had a large mural thrombus surface area or were accompanied by aneurysm of the iliac or femoral artery. "
|1.||Plasminogen Activator Inhibitor 1
|4.||fibrin fragment D (D-dimer)
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|6.||Fibrinogen (Factor I)
|8.||formycin diphosphate (FDP)
|10.||antithrombin III-protease complex
|2.||Dilatation and Curettage (D&C)
|4.||Homologous Transplantation (Allograft)